Please login to the form below

Not currently logged in
Email:
Password:

rilpivirine

This page shows the latest rilpivirine news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

The advisory committee issued a positive opinion for Juluca - which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by Johnson &Johnson’s

Latest news

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    The US regulator gave a green light to Juluca, which combines ViiV’s integrase inhibitor Tivicay (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) developed by J&J’s ... The company is also testing the

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    It is also investigating a dual therapy based on integrase inhibitor  cabotegravir and rilpivirine that could be given as a monthly or bi-monthly injection as an alternative to daily doses ... Data from the SWORD studies supported our hypothesis that a

  • ViiV takes two-drug cocktail for first-line HIV into phase III ViiV takes two-drug cocktail for first-line HIV into phase III

    In addition to the Tivicay/Epivir combination, ViiV is also investigating a dual therapy based on integrase inhibitor cabotegravir and Johnson &Johnson's non-nucleoside RTI rilpivirine that could be given ... It also has an oral dolutegravir/rilpivirine

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    The once-daily, single-tablet combines TAF with emtricitabine - a dual therapy sold as Descovy - with Johnson &Johnson's Edurant (rilpivirine). ... It is a follow up to Gilead's $1.4bn Complera, which contains emtricitabine, rilpivirine and tenofovir

  • Gilead bags EU approval for next-generation HIV drug Gilead bags EU approval for next-generation HIV drug

    Descovy was approved by the US FDA earlier this month, while a three-drug combination called Odefsey (emtricitabine, rilpivirine and TAF) - a follow-up to its $1.4bn Complera product - was

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics